Replimune Group, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| REPL | 2126.HK | BINV.ST | SNDX | SLS | CBIO | |
|---|---|---|---|---|---|---|
| Market cap | 1.96B | 1.11B | 240.84M | 940.80M | 1.85B | 513.37M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -30.8 | -3.0 | -0.9 | -14.4 | -91.4 | -5.3 |
| Price/book | 9.6 | 2.0 | 1.2 | -54.7 | 13.4 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +140.68% | −29.57% | −88.59% | −5.36% | +427.98% | +5.07% |
| Today | +0.19% | +7.91% | +2.09% | −26.87% | +3.04% | +5.82% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All REPL news ›Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians
Dean Drobot via Canva Replimune Group (REPL) shares jumped 17% today on its first update on the TUDRIQEV melanoma launch. The launch reaches two bigger names. TUDRIQEV is an oncolytic virus, like Imlygic from Amgen (AMGN), and it’s given…
Replimune Group (NASDAQ:REPL) Stock Rating Upgraded by Wall Street Zen
Posted by Defense World Staff on Oct 31st, 2026 Replimune Group (NASDAQ:REPL – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall…
Replimune announces Tudriqev now available in U.S. for advanced melanoma
Replimune (REPL) Group announced that Tudriqev is now commercially available in the United States. Tudriqev is indicated in combination with niv... Replimune announces Tudriqev now available in U.S. for advanced melanoma Replimune (REPL)…
Replimune price target raised to $29 from $24 at Jefferies
Jefferies analyst Roger Song raised the firm’s price target on Replimune (REPL) to $29 from $24 and keeps a Buy rating on the shares. Three week... Replimune price target raised to $29 from $24 at Jefferies Jefferies analyst Roger Song…
Replimune: 3 Key Takeaways for Long-Term Investors
Replimune launched TUDRIQEV as its first commercial product, marking a transition from clinical development to commercial execution. Within 20 business days of product availability, more than 15 medical centers wrote prescriptions, and 20…
Replimune anticipates permanent J-code by April 2027 as TUDRIQEV launch metrics build
Replimune Q2 FY2027 earnings call: TUDRIQEV launch momentum, early melanoma uptake, cash runway, and key risks. Earnings Call Insights: Replimune Group, Inc. (REPL) Q2 fiscal 2027 - "This is a defining moment for Replimune. TUDRIQEV is the…
Replimune (REPL) Q2 2027 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Replimune's Second Quarter Fiscal 2027 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to your first speaker, Arleen…
More from 1 other outlet
Replimune Group GAAP EPS of -$0.54 beats by $0.21
Replimune Q2 earnings beat estimates, with cash rising to $307.8M and R&D costs falling. - Replimune Group press release (REPL): Q2 GAAP EPS of -$0.54 beats by $0.21. - As of September 30, 2026, cash and cash equivalents were $307.8…
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
Aug 27, 2026, 04:16 ET Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in…
Repsol (REPYF) Projected to Post Quarterly Earnings on Thursday
Posted by Sarita Garza on Oct 27th, 2026 Repsol (OTCMKTS:REPYF – Get Free Report) will likely be posting its results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $2.72 per share and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- seekingalpha.com4
- prnewswire.com3
- themarketsdaily.com3
- fool.com2
- markets.businessinsider.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.